References
- Lipinski CJ. (2001). Avoiding investment in doomed drugs. Is poor solubility an industry wide problem? Curr Drug Dis, 4:17–9.
- Lipinski CJ. (2002). Poor aqueous solubility-an industry wide problem in drug discovery. Am Pharm Rev, 5:82–5.
- Lennernäs H. (1998). Human intestinal permeability. J Pharm Sci, 87:403–10.
- Lennernäs H. (2007). Animal data: the contributions of the using chamber and perfusion systems to predicting human oral drug delivery in vivo. Adv Drug Deliv Rev, 59:1103–20.
- Nernst W, Brunner E. (1904). Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Z Physik Chemie, 47:52–110.
- Liversidge GG, Cundy K. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91–7.
- Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol, 56:827–40.
- Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K, . (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A beagle dog model predits improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135–46.
- Li X, Gu l, Xu Y, Wang Y. (2009). Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats. Drug Dev Ind Pharm, 35:827–33.
- Kamiya S, Kurita T, Miyagishima A, Arakawa M. (2009). Preparation of griseofulvin nanoparticle suspension by high-pressure homogenization and preservation of the suspension with saccharides and sugar alcohols. Drug Dev Ind Pharm, 35:1022–8.
- Muller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3–19.
- Jia L, Wong H, Wang Y, Garza M, Weitman SD. (2003). Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J Pharm Sci, 92:161–72.
- Merisko-Liversidge E, Liversidge GG, Cooper ER. (2003). Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Biopharm, 18:113–20.
- Hecq J, Deleers M, Fanara D, Vranckx H, Boulanger P, Le lamer S, . (2006). Preparation ad in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base. Eur J Pharm Biopharm, 64:360–8.
- Keck CM, Muller RH. (2006). Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm, 62:3–16.
- Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing – Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631–44.
- Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–96.
- Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–20.
- Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, . (2002). Biopharmaceutics classification system: The scientific basis for biowaiver extensions. Pharm Res, 19:921–5.
- Ziller KH, Rupprecht HH. (1990). Control of crystal growth in drug suspensions. Part II: influence of polymers on dissolution and crystallization during temperature cycling. Pharm Ind, 52:1017–22.
- Sigfridsson K, Forssen S, Holländer P, Skantze U, de Verdier J. (2007). A formulation comparison, using solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm, 67:540–7.
- Liversidge GG, Conzentino P. (1995). Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309–13.
- Jia L, Wong J, Cerna C, Weitman S. (2002). Effect of nanonization on absorption of 301029: Ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res, 19:1091–6.
- Dressman JB, Reppas C. (2000). In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11:73–80.
- Mouton JW, van Peer A, de Beule K, van Vliet A, Donnelly JP, Soons PA. (2006). Pharmacokinetics of intraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother, 50:4096–102.
- Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. (2008). Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm, 350:338–43.